LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T
All content for Oncology Data Advisor is the property of i3 Health and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1
Oncology Data Advisor
25 minutes 39 seconds
3 months ago
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.
In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!
Click here to claim you CE credit for this activity: https://bit.ly/45u106o
Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO
Oncology Data Advisor
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T
